FLGT
Fulgent Genetics, Inc. Health Care Services-Medical Laboratories Russell 3000
$20.62Close
$640.9MMarket cap
$13.79 – $30.8552-week range
Nov 5, 2026Next report · after the close
Highlights
Cautions
- Not in an uptrend 3 of 8 trend conditions
- Far from its high 33% below its 52-week high
- Results soon Nov 5, 2026, in 4 days
Price
Filing Results Screen pick 52-week high and low Adjusted prices
Key figures
Off 12-month high
33%
1wk
up 2.6%
price change
1mo
down 6.4%
price change
12-month return
down 9%
market up 11% ·
its own down 20%
F-score
4 / 9
Weak
Altman Z″
14.37
Low risk
P/E
—
price / earnings
PEG
—
P/E / EPS growth
P/B
0.6×
price / book
Earnings yield
down 15.4%
EBIT / enterprise value
Cheaper than
36%
of the market · expensive
Revenue growth
up 14%
year on year
EPS growth
—
latest quarter
Sales growth
up 4%
latest quarter · +8 pts
ROE
down 5%
return on equity
Free cash margin
down 38%
-$124.2M FCF
D/E
0.00
long-term debt / equity
Net debt / EBITDA
—
Interest cover
—EBIT / interest
Piotroski tests
- not yet profitable on its assets
- operating cash flow is negative
- profitability slipped from last year
- profits not fully backed by cash
- issued more shares
- reduced long-term debt
- short-term liquidity improved
- gross margin widened
- assets working harder
Repair signals
- Long-term debt down 21% ($0.0B → $0.0B)
- Gross margin 37.8% → 40.6%
- Revenue reaccelerating (-2% then +14%)
Trade setup
ATR%
3.9%
$0.80 a day · 2×ATR $19.03
RS
62 / 99
vs the universe
Trend
3 / 8
trend template
Relative volume
0.7×
vs 50-day average
Up/down volume
1.23
50 sessions
Implied move
—
no option chain · report Nov 5, 2026
Trend template · 3 of 8
- Price above the 150 and 200-day averages: passes
- 150-day average above the 200-day: fails
- 200-day average rising for a month: fails
- 50-day average above the 150 and 200-day: passes
- Price above the 50-day average: fails
- At least 30% above the 52-week low: passes
- Within 25% of the 52-week high: fails
- RS rank 70 or higher: fails
Screen verdict
Did not qualify for any screen.
Warning signs
- No restatement or impairment
- Equity positive
- Interest covered
- No material dilution
- Profits tracking cash
- Margins and revenue not shrinking
Last reported
Jul 30, 2026
Last shock
Jul 31, 2026-18% in one session4.3× volumeon results+25% since
Financials
- Gross 41%
- Net -19%
- Free cash -38%
- Cash
- Long-term debt
| FY2020Dec 31, 2020 | FY2021Dec 31, 2021 | FY2022Dec 31, 2022 | FY2023Dec 31, 2023 | FY2024Dec 31, 2024 | FY2025Dec 31, 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $421.7M | $992.6M | $619.0M | $289.2M | $283.5M | $322.7M |
| Gross margin | 79% | 78% | 59% | 36% | 38% | 41% |
| Operating income | $290.2M | $676.0M | $178.5M | -$195.5M | -$73.9M | -$91.1M |
| Net income | $214.3M | $507.4M | $143.4M | -$167.8M | -$42.7M | -$60.5M |
| Net margin | 51% | 51% | 23% | -58% | -15% | -19% |
| Earnings per share | $8.91 | $16.38 | $4.63 | -$5.63 | -$1.41 | -$1.97 |
| Free cash flow | $105.5M | $514.8M | $234.7M | $4.8M | -$19.3M | -$124.2M |
| Free cash margin | 25% | 52% | 38% | 2% | -7% | -38% |
| Cash | $87.4M | $164.9M | $79.5M | $97.5M | $55.1M | $50.2M |
| Long-term debt | — | — | $3.4M | $3.0M | $2.5M | $2.0M |
| Shareholders' equity | $569.4M | $1.2B | $1.3B | $1.1B | $1.1B | $1.1B |
| Shares outstanding | 28.18m | 30.16m | 29.44m | 29.65m | 30.84m | 31.08m |
Filings
| Filed | Report | Period to | Lag |
|---|---|---|---|
| Jul 30, 2026 | Quarterly ↗ | Jun 30, 2026 | 30d |
| May 1, 2026 | Quarterly ↗ | Mar 31, 2026 | 31d |
| Feb 27, 2026 | Annual ↗ | Dec 31, 2025 | 58d |
| Nov 7, 2025 | Quarterly ↗ | Sep 30, 2025 | 38d |
| Aug 1, 2025 | Quarterly ↗ | Jun 30, 2025 | 32d |
| May 2, 2025 | Quarterly ↗ | Mar 31, 2025 | 32d |
| Feb 28, 2025 | Annual ↗ | Dec 31, 2024 | 59d |
| Nov 8, 2024 | Quarterly ↗ | Sep 30, 2024 | 39d |
| Aug 2, 2024 | Quarterly ↗ | Jun 30, 2024 | 33d |
| May 3, 2024 | Quarterly ↗ | Mar 31, 2024 | 33d |
| Feb 28, 2024 | Annual ↗ | Dec 31, 2023 | 59d |
| Nov 3, 2023 | Quarterly ↗ | Sep 30, 2023 | 34d |
Current reports
| Filed | Disclosed |
|---|---|
| Jul 30, 2026 | Results · Regulation FD ↗ |
| Jun 2, 2026 | Other events ↗ |
| May 21, 2026 | Other events ↗ |
| May 14, 2026 | Director or officer change · Shareholder vote ↗ |
| May 1, 2026 | Results · Regulation FD ↗ |
| Mar 17, 2026 | Material agreement · Acquisition or disposal · Regulation FD ↗ |
| Feb 27, 2026 | Results · Regulation FD ↗ |
| Dec 22, 2025 | Material agreement · Other events ↗ |
| Nov 7, 2025 | Results · Regulation FD ↗ |
| Oct 20, 2025 | Other events ↗ |
| Aug 1, 2025 | Results · Regulation FD ↗ |
| May 15, 2025 | Shareholder vote ↗ |